🇺🇸·8h agoIndustry
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
Publisher
A
Abeona Therapeutics
USA
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Abeona Therapeutics
- Region
- USA
- Scope
- Industry
- Published
- September 18, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on investors.abeonatherapeutics.com
Leave the platform to read the original full article on the publisher site.
Source: Abeona Therapeutics
Scope: Industry
Related coverage
More related coverage
Certara/3h ago
When EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosing
Certara/3h ago
Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers
AbbVie News/7h ago
AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
Bristol-Myers Squibb News/8h ago